Accord Healthcare, Inc., a UK-based generic pharmaceutical company, announced on Tuesday that it has added Lurasidone HCL tablets to its range of generic drugs.
Accord's product is AB-rated to Sunovion Pharma's Latuda and is being offered in 20mg, 40mg, 60mg, 80mg, and 120mg doses in 30-count bottles.
The company said that Lurasidone is an oral, atypical antipsychotic, which is a first-line treatment option for the management of schizophrenia in adults and adolescents. Atypical antipsychotics have lower potential for extrapyramidal side effects. Laurasidone is claimed to rebalance dopamine and serotonin to improve thinking, mood, and behaviour.
Divya Verma, Accord Healthcare vice president, Marketing & Portfolio, said, 'By offering lurasidone, we hope to reduce the burden of costs of long-term treatment for individuals who can benefit from this medication. A generic option in mental health treatment provides more accessible healthcare to those who are in need.'
Accord Healthcare launches Lurasidone HCL tablets
US FDA Accepts the ATI-1501 NDA, According to Appili Therapeutics
Sanofi reports Q4 sales of Dupixent up 42%
Upsher-Smith Laboratories launches Fluoxetine Oral Solution, USP, 20mg/5mL
Astellas Pharma enters into Asset Purchase Agreement with Sandoz
ANI Pharmaceuticals Launches Levocarnitine Tablets USP Following US FDA Approval
Hartness Named to Bryn Pharma Board of Directors
Accord Healthcare adds Bendamustine Lyo. Injection to range of chemotherapy drugs
ANI Pharmaceuticals Receives FDA Approval, Launches Fluoxetine Oral Solution USP
ANI Pharmaceuticals receives FDA approval for Fluoxetine Oral Solution USP
Prasco Laboratories introduces Authorised Generic of ZIOPTAN in partnership with Thea Pharma
ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
McKinley, Boothe Named to Maxwell Biosciences Board of Directors